Michael J. Eckart

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

Luca Gianni, Urania Dafni, Richard D. Gelber et al. · The Lancet Oncology · 2011 · 611 citations

Medicine, Oncology, Breast Oncology +13

Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

Kirsten Fischer, Paula Cramer, Raymonde Busch et al. · Journal of Clinical Oncology · 2011 · 372 citations

Medicine, Oncology, Pharmacotherapy +14

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Rüdiger Hehlmann, Michael Lauseker, Susanne Saußele et al. · Leukemia · 2017 · 339 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt et al. · Blood · 2014 · 276 citations

Medicine, Hematology, Oncology +12

CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs

Regina Jitschin, Martina Braun, Maike Büttner et al. · Blood · 2014 · 240 citations

Life Sciences, Hematology, Immunology +14